Thursday, September 29, 2022
Home Tags Dupixent

Tag: Dupixent

Regeneron announces FDA approval for Dupixent to treat prurigo nodularis

A regulatory filing for prurigo nodularis is under review by the European Medicines Agency.

Regeneron receives FDA appoval for Dupixent use for pediatric patients

A similar review is underway by the European Medicines Agency.

Regeneron, Sanofi restructure Kevzara, Praluent collaboration

Under the new agreement, Paris-based Sanofi would gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent, while Tarrytown’s Regeneron would gain sole U.S. rights to Praluent.

Regeneron moves closer to European approval of drug for asthma

In the U.S., it is indicated for use by prescription to treat moderate-to-severe atopic dermatitis, also known as eczema.

Regeneron dermatitis drug Dupixent approved in Japan

The antibody drug was approved for use in the U,S. last March.

Regeneron dermatitis drug approved for European market

The antibody drug will be marketed as Dupixent and available to adults with moderate to severe atopic dermatitis .

FDA approves new Regeneron drug treating severe eczema

Dupixent will go on the U.S. market this week as the first antibody medicine for uncontrolled itching and rashes in adults with atopic dermatitis.

Regeneron’s net income jumps 40 percent to $1.3 billion in 2016

Total revenues in 2016 for Regeneron, the state’s largest biopharmaceutical employer, rose to $4.86 billion, an 18 percent increase from the previous year.